Acromegaly

SAN FRANCISCO — Most adults with acromegaly reduced IGF-1 levels and improved acromegaly symptoms with once-monthly subcutaneous octreotide depot, according to new research.

A machine learning model was more accurate than 12 experienced endocrinologists in identifying adults with acromegaly based on voice recordings, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

The FDA announced that tirzepatide, a GIP/GLP-1 dual agonist approved for the treatment of type 2 diabetes and obesity, has been removed from its drug shortage list.

A generic version of a treatment for acromegaly is now available for adults in the U.S., according to an industry press release.

Having high insulin-like growth factor I levels over a longer duration increased risk for cancer among adults with acromegaly, but not for those with nonfunction pituitary adenoma, according to study data.

BOSTON — In this video exclusive, Maria Fleseriu, MD, FACE, discusses some of the top adrenal and pituitary news from ENDO 2024.

BOSTON — The majority of people with acromegaly receiving oral octreotide achieve a biochemical response, regardless of their baseline insulin-like growth factor I level, according to data from a post hoc analysis.

BOSTON — Adults with acromegaly previously controlled with standard of care experienced similar disease control with once-monthly injectable octreotide at 24 and 52 weeks, with no serious adverse events, data presented at ENDO 2024 show.

More than half of adults with acromegaly receiving a novel once-daily oral medication achieved an insulin-like growth factor-1 level at or below the upper limit of normal, according to topline results from the PATHFNDR-2 trial.

More than 80% of adults with acromegaly achieved an insulin-like growth factor level at or below the upper limit of normal at 36 weeks with an investigational once-daily oral medication, according to topline results from a phase 3 trial.